Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by B. Franks
Persistence and Adherence With Mirabegron, a New Beta-3 Receptor Agonist, Versus Antimuscarinics in Overactive Bladder: Early Experience in Canada
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Related publications
Mirabegron: A Beta-3 Agonist for Overactive Bladder
The Consultant Pharmacist
Mirabegron &Ndash; A Selective &Szlig;3-Adrenoreceptor Agonist for the Treatment of Overactive Bladder
Research and Reports in Urology
Urology
New Developments in the Management of Overactive Bladder: Focus on Mirabegron and onabotulinumtoxinA
Therapeutics and Clinical Risk Management
Discovery of Vibegron: A Potent and Selective 3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder
Adverse Event Assessment of Antimuscarinics for Treating Overactive Bladder: A Network Meta-Analytic Approach
PLoS ONE
Multidisciplinary
Pd26-10 Onabotulinumtoxina Provides Early and Consistent Improvements in Overactive Bladder Symptoms and Quality of Life Outcomes in Patients With Overactive Bladder
Journal of Urology
Urology
Efficacy and Tolerability of Mirabegron in Female Patients With Overactive Bladder Symptoms After Surgical Treatment for Stress Urinary Incontinence
International braz j urol : official journal of the Brazilian Society of Urology
Medicine
Urology
Treatment Success for Overactive Bladder With Urinary Urge Incontinence Refractory to Oral Antimuscarinics: A Review of Published Evidence
BMC Urology
Medicine
Reproductive Medicine
Urology
Factors Associated With Improvements in Patient-Reported Outcomes During Mirabegron or Antimuscarinic Treatment of Overactive Bladder Syndrome: A Registry Study (PERSPECTIVE)
Advances in Therapy
Medicine
Pharmacology
